Liu Yihai, Zhang Wenfeng, Hu Tingting, Ni Jie, Xu Biao, Huang Wei
Department of Cardiology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University.
Department of Cardiology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University;
J Vis Exp. 2020 May 16(159). doi: 10.3791/61158.
Dilated cardiomyopathy (DCM) refers to a spectrum of heterogeneous myocardial disorders characterized by ventricular dilation and depressed cardiac performance in the absence of hypertension, valvular, congenital, or ischemic heart diseases, and which may be related to infection, autoimmune or metabolic abnormalities, or family inheritance. It can progress into congestive heart failure with a poor prognosis. Doxorubicin (Dox) is widely employed as a chemotherapeutic drug, but its use is limited because it causes DCM-like changes of the myocardium. Its myocardial toxicity is attributed to oxidative stress, chronic inflammation, and cardiomyocyte apoptosis. A model of DCM exploiting these Dox-induced DCM symptoms has not been established.
扩张型心肌病（DCM）是指一系列异质性心肌疾病，其特征为心室扩张且心脏功能降低，同时不存在高血压、瓣膜性、先天性或缺血性心脏病，可能与感染、自身免疫或代谢异常或家族遗传有关。它可进展为充血性心力衰竭，预后较差。阿霉素（Dox）被广泛用作化疗药物，但其使用受到限制，因为它会引起类似DCM的心肌变化。其心肌毒性归因于氧化应激、慢性炎症和心肌细胞凋亡。利用这些阿霉素诱导的DCM症状的DCM模型尚未建立。
